| abstract |
The present invention relates to α v β 3 integrin target single domain antibodies and various applications thereof. The α v β 3 integrin target single domain antibody of the present invention exhibits high binding ability, good tissue permeability and biostability to α v β 3 integrins associated with neovascularization compared to conventional antibodies. In addition, the single domain antibody of the present invention can be easily measured in vitro, in vivo or ex vivo by binding to fluorescent particles, and thus effective in detecting angiogenesis and diagnosing related diseases, and thus can be usefully used in related industries. . |